The Effects of Yogurt on Gut Microbiome and Metabolism in H. Pylori.
NCT ID: NCT05374980
Last Updated: 2023-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
51 participants
INTERVENTIONAL
2022-01-01
2023-02-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to investigate whether the gut microbiota and insulin resistance of patients with H. pylori infection are abnormal. In addition, whether drinking fermented milk product with probiotic reduces Helicobacter pylori, improves gut microbiota, and increases butyrate-producing bacteria and insulin resistance.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Probiotics on Gut Microbiota During the Helicobacter Pylori Eradication
NCT05662514
Efficacy of Probiotics in the Gut Microbiota and H Pylori Density
NCT02725138
Effects of Fermented Dairy Products on Defecation Changes Through Gut Microbiota
NCT06862310
Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders
NCT02900196
Control of Helicobacter Pylori Infection by Probiotics
NCT01115296
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Yogurt
Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
Yogurt
Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
Placebo
Drink a bottle of 200ml placebo every morning and evening for 8 weeks
Placebo
Drink a bottle of 200ml placebo every morning and evening for 8 weeks
Healthy volunteer
Patients with Helicobacter pylori negative (ΔUBT\<2%) need blood test and collect stool samples at first, and collect stool samples again after 2 months.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yogurt
Drink a bottle of 200ml yogurt every morning and evening for 8 weeks
Placebo
Drink a bottle of 200ml placebo every morning and evening for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Negative gastric Helicobacter (ΔUBT\<2%) matching age, gender, and body mass index.
Exclusion Criteria
2. Patients with acute diseases, such as respiratory tract infection, acute gastroenteritis.
3. In the past three months, those who have had dyspepsia but have not undergone gastroscopy, or have a history of active gastrointestinal ulcers and gastrointestinal bleeding.
4. Those who have had gastrointestinal cancer or have undergone gastrointestinal surgery.
5. Those who are unwilling to delay receiving Anti-H. pylori therapy.
6. Newly diagnosed cancer (except basal cell carcinoma) or cancer treatment in the past 5 years.
7. People who have had cardiovascular disease, respiratory disease, autoimmune disease, mental disease or other chronic diseases that are not well controlled, such as myocardial infarction or stroke, chronic obstructive pulmonary disease, inflammatory bowel disease, Schizophrenia.
8. Diabetes and those who are or need to take drugs.
9. Those who have used the following drugs in the past month: antibiotics, NSAIDs, obesity drugs, steroid therapy, proton pump inhibitors, bismuth agents.
10. In the past month, regularly consume the following foods (at least 2 times a week): probiotics, prebiotics, or any foods containing probiotics, dairy products (yogurt, cheese), Chinese medicine, kimchi, miso, honey, cranberry, spicy food.
11. Fecal occult blood positive, unexplained iron-deficiency anemia, weight increase or decrease by more than 5% within six months.
12. Abnormal liver function index (AST, ALT or ALP greater than 2 times the upper limit of normal), abnormal renal function index (eGFR less than 45 ml/min).
13. Pregnant or breast-feeding women.
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taichung Veterans General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Han-Chung, Lien
Principle Investigator of Gastrointestinal Motility Lab
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Han-Chung Lien, MDPHD
Role: PRINCIPAL_INVESTIGATOR
Taichung Veterans General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taichung Veterans General Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009 May;136(6):1863-73. doi: 10.1053/j.gastro.2009.01.073. Epub 2009 May 7.
Sugizaki K, Tari A, Kitadai Y, Oda I, Nakamura S, Yoshino T, Sugiyama T. Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan. Helicobacter. 2018 Apr;23(2):e12474. doi: 10.1111/hel.12474. Epub 2018 Mar 4.
Butt J, Varga MG, Blot WJ, Teras L, Visvanathan K, Le Marchand L, Haiman C, Chen Y, Bao Y, Sesso HD, Wassertheil-Smoller S, Ho GYF, Tinker LE, Peek RM, Potter JD, Cover TL, Hendrix LH, Huang LC, Hyslop T, Um C, Grodstein F, Song M, Zeleniuch-Jacquotte A, Berndt S, Hildesheim A, Waterboer T, Pawlita M, Epplein M. Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. Gastroenterology. 2019 Jan;156(1):175-186.e2. doi: 10.1053/j.gastro.2018.09.054. Epub 2018 Oct 6.
Park H, Park JJ, Park YM, Baik SJ, Lee HJ, Jung DH, Kim JH, Youn YH, Park H. The association between Helicobacter pylori infection and the risk of advanced colorectal neoplasia may differ according to age and cigarette smoking. Helicobacter. 2018 Jun;23(3):e12477. doi: 10.1111/hel.12477. Epub 2018 Mar 29.
Chen TP, Hung HF, Chen MK, Lai HH, Hsu WF, Huang KC, Yang KC. Helicobacter Pylori Infection is Positively Associated with Metabolic Syndrome in Taiwanese Adults: a Cross-Sectional Study. Helicobacter. 2015 Jun;20(3):184-91. doi: 10.1111/hel.12190. Epub 2015 Jan 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SF19354B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.